Foundation Medicine, Inc. is a public American company based in Cambridge, Massachusetts which develops, manufactures and sells genomic analysis diagnostics for solid and circulating cancers. The companys tests are based on next-generation sequencing technology. Foundation Medicine went public in August 2013; its stock is traded on the New York Stock Exchange under the symbol FMI. As of December 2014[update], the company had 275 employees.
Highest paying job titles at Foundation Medicine include Medical Director, Senior Software Engineer, and Director of Life Sciences